ANUAL GENERAL MEETING
2021
June 22, 2021
HARNESSING THE FULL
POTENTIAL OF THE
IMMUNESYSTEM
ANNUAL GENERAL MEETING 2021
AGENDA
1 | Presentation of the adopted annual financial statements, the approved consolidated financial statements, and the combined |
management report for the Company and the Group as well as the report of the Supervisory Board for the Company, each | |
for the financial year 2020 or as at 31 December 2020, respectively | |
2 | Approval of the actions of the Management Board |
3 | Approval of the actions of the Supervisory Board |
4 | Appointment of the auditor for the 2021 financial year |
5 | Resolution on the revocation of the existing authorized capital and the creation of a new authorized capital (Authorized |
Capital 2021) against contributions in cash and/or in kind with the possibility of excluding subscription rights and | |
corresponding amendments to the Articles of Association | |
6 | Amendment of the authorization to issue stock options |
7 | Resolution on the partial revocation and amendment of the current authorization to issue stock options (Stock Option |
Program 2017/2019) and on the partial revocation of Conditional Capital ESOP 2017/2019; Resolution on the authorization | |
to issue stock options (Stock Option Program 2021) and on the implementation of a new Conditional Capital 2021 and | |
corresponding amendments to the Articles of Association | |
8 | Amendment to the existing authorization to acquire treasury shares and their use, also excluding subscription rights |
2
ANNUAL GENERAL MEETING 2021
AGENDA (2)
9 | Extending the authorization to acquire treasury shares and to use them, also excluding subscription rights |
- Resolution on the approval of the system for the compensation of the members of the Management Board
- Resolution on the compensation and on the compensation system for the members of the Supervisory Board and an amendment of Sec. 9 para. 6 of the Articles of Association
- Resolution on the revocation of the resolution of the Company's Annual General Meeting of June 26, 2020 (agenda item 8 letter d)) on the consent to the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company
- Conclusion of inter-company agreements
- Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company
- Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company with BioNTech Manufacturing Marburg GmbH as dependent company
- Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and reSano GmbH as dependent company
3
MANAGEMENT BOARD REPORT
-
OPERATING DEVELOPMENT 2020 / Q1 2021 and OPERATING OUTLOOK 2021
Prof. Dr. Ugur Sahin, CEO & Founder - FINANCIAL DEVELOPMENT 2020 / Q1 2021 and FINANCIAL OUTLOOK 2021
Dr. Sierk Pötting, CFO & COO
4
2021
Capitalizing on COVID-19
Vaccine Success
to Accelerate Execution
on our Vision
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
BioNTech SE published this content on 22 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2021 17:40:06 UTC.